RxDoctor Payments DataLook up a doctor →

Wynne Huang, MD

Family Medicine · Woburn, MANPI 1306882741

Payments from drug & device makers

$17,195in general payments, 2019–2025

Across 760 payments — averaging $22.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$4K
  • AstraZeneca$2K
  • Amgen$2K
  • Novo Nordisk$1K
  • Pfizer$787
  • Boehringer Ingelheim$736
  • plus $6K from 33 others

What the payments were for

  • Food & beverage$17,06899%
  • Education$1271%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$17,195 in reported general payments places this provider in the 95th percentile of 1,049 family medicine providers in Massachusetts.

See all family medicine providers in Massachusetts

Medicare billing

Part B allowed, 2024
$10,835
Medicare patients
54
Services billed
99

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide41$46,003
EliquisApixaban39$36,397
MounjaroTirzepatide13$24,452
Trelegy ElliptaFluticasone/Umeclidin/Vilanter20$22,785
Breztri AerosphereBudesonide/Glycopyr/Formoterol16$19,339
JardianceEmpagliflozin12$13,549
MyrbetriqMirabegron13$9,242
OxycontinOxycodone Hcl13$8,158
LinzessLinaclotide12$7,182
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr13$5,947
Atorvastatin Calcium201$2,459
Lantus SolostarInsulin Glargine,hum.Rec.Anlog12$1,939
Metoprolol Succinate110$1,727
Gabapentin58$1,425
Omeprazole94$1,399

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$1,033$46,00341 claims
PfizerEliquis$787$36,39739 claims
GSKTrelegy Ellipta, Anoro Ellipta$433$28,73233 claims
Lilly USA, LLCMounjaro$479$24,45213 claims
AstraZenecaBreztri Aerosphere$2,419$19,33916 claims
Boehringer IngelheimJardiance$736$13,54912 claims
Astellas Pharma US IncMyrbetriq$267$9,24213 claims
AbbVieLinzess, Synthroid$4,420$8,38329 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,049 family medicine providers in Massachusetts.

Other family medicine in Woburn

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →